Craneware plc

Craneware plc

1,106.00
GBX
-8.00
(-0.72%)
74.71BMarket Cap
Mar 08Next Earn
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
1.58
1.67
1.86
2.15
2.5
2.68
2.67
2.82
4.72
4.95
5.41
- -
- -
- -
Basic EPS, GAAP
0.32
0.35
0.39
0.5
0.59
0.56
0.63
0.48
0.27
0.26
0.33
- -
- -
- -
Free Cash Flow per Basic Share
0.28
0.69
0.48
0.49
0.94
0.11
0.4
0.87
0.76
2.79
1.16
- -
- -
- -
Dividend per Share
0.2
0.2
0.22
0.24
0.29
0.32
0.34
0.36
0.37
0.34
0.37
- -
- -
- -
Book Value per Share
1.66
1.78
1.97
2.2
1.94
2.24
2.55
7.88
9.37
9.28
9.3
- -
- -
9.29
Tangible Book Value per Share
1.13
1.17
1.35
1.47
1.06
1.1
1.18
6.58
-3.74
-3.51
-3.08
- -
- -
-2.83
Basic Weighted Avg Shares
27
27
27
27
27
27
27
27
35
35
35
35
35
35
Sales/Revenue/Turnover
43
45
50
58
67
71
71
76
166
174
189
- -
- -
- -
Operating Margin (%)
26.47
28.05
28.91
28.55
27.72
26.95
26.88
26.16
11.23
9.86
11.01
- -
- -
- -
Depreciation Expense
2
1
2
1
2
4
5
5
29
32
33
- -
- -
- -
Net Income, GAAP
9
9
11
14
16
15
17
13
9
9
12
- -
- -
- -
Effective Tax Rate (%)
23.74
24.87
24.05
19.89
16.56
18.21
12.78
1.97
28.19
29.45
25.68
- -
- -
- -
Profit Margin (%)
20.22
20.95
21.22
23.4
23.55
20.99
23.55
17.08
5.68
5.31
6.18
- -
- -
- -
Working Capital
28
27
29
31
18
20
24
206
10
-13
-56
- -
- -
-51
LT Debt
- -
- -
- -
- -
- -
- -
2
1
105
77
31
- -
- -
27
Total Equity
45
48
53
59
52
60
68
260
333
328
329
- -
- -
329
Return on Invested Capital (%)
19.64
19.94
20.54
23.73
28.65
26.69
25.76
7.81
3.7
3.17
3.74
- -
- -
- -
Return on Capital (%)
19.97
20.29
21.06
24.12
28.46
26.88
25.79
7.78
3.66
3.18
3.96
- -
- -
- -
Return on Common Equity (%)
19.97
20.29
21.06
24.12
28.46
26.88
26.26
7.85
3.17
2.79
3.57
- -
- -
- -

Capital Structure

USD

•

in mil. unless spec.
Dec'24
Jun'24
Dec'25
ST Debt
9
9
9
LT Borrowings
51
27
24
LT Finance Leases
2
4
3
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
35
35
35
Market Capitalization
786
1,032
935

Working Capital

USD

•

in mil. unless spec.
Dec'24
Jun'24
Dec'25
Total Current Assets
119
93
126
Cash, Cash Equivalents & STI
64
35
72
Accounts Receivable, Net
41
45
35
Inventories
- -
- -
- -
Total Current Liabilities
154
149
177
Payables & Accruals
- -
- -
- -
ST Debt
9
9
9
Deferred Revenue
- -
- -
- -

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
- -
Free Cash Flow
- -
- -
- -
Net Income, GAAP
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

USD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
189
2025
- -
- -
- -
2026
- -
- -
- -

Semi-annual Earnings Per Share

USD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
0.33
2025
- -
- -
- -
2026
- -
- -
- -

Semi-annual Dividends Per Share

USD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
0.37
2025
- -
- -
- -
2026
- -
- -
- -

Company Description

CEO
Keith Neilson
Full Time Employees
765
Sector
Technology services
Industry
Packaged software
Address
1 Tanfield Edinburgh SC United Kingdom EH3 5DA
IPO Date
Sep 13, 2007
Business
Craneware plc (LSE: CRW) develops and provides mission-critical SaaS solutions for the healthcare sector, with a primary focus on revenue integrity, patient engagement, and financial performance management for hospitals and health systems. The company offers a comprehensive suite of products including Trisus Revenue Cycle, its flagship platform for end-to-end revenue cycle management; ChargeTRUE for automated charge capture and compliance; Trisus Decision Analytics for data-driven insights; Patient Engagement Portal for streamlined billing and payments; and Value Analytics for optimizing reimbursement strategies; as well as services encompassing implementation, training, managed services, and ongoing support. Craneware primarily serves acute care hospitals, integrated delivery networks, and children's hospitals in the United States, its core market, with expanding operations in the United Kingdom and select international regions. Founded in 1996 and headquartered in Edinburgh, Scotland, the company operates as a standalone entity listed on the London Stock Exchange's AIM market. In recent developments, Craneware completed the acquisition of Clinion in late 2023, enhancing its pharmacy revenue integrity capabilities and marking a strategic expansion into specialized clinical workflows. The company reported robust growth in fiscal 2025, driven by strong recurring SaaS revenue and new client wins, including major U.S. health systems adopting its Trisus platform amid rising demand for revenue optimization tools. Additionally, Craneware announced partnerships with leading electronic health record (EHR) providers to integrate its solutions more seamlessly, supporting broader adoption in value-based care environments.

Company News

  • Craneware plc (CRWRF) Q4 2026 Earnings Call Transcript

  • Craneware sinks 25% as Peel Hunt cuts forecasts after cyber warning

  • Craneware resets revenue expectations to $185 million after cyber incident as profit rises

  • Craneware (OTCMKTS:CRWRF) Stock Price Down 2.2% – What’s Next?

  • Craneware reveals cyber attack with employee and customer data stolen

  • Craneware shares slump after slower conversion triggers profit warning

  • Craneware plc (CRWRF) Q2 2026 Earnings Call Prepared Remarks Transcript

  • Craneware (OTCMKTS:CRWRF) Trading Down 24.5% – What’s Next?